Education
Smokeout 2025: Latest on Hazards of Tobacco, Life-Saving Benefits of Quitting Now
5 min. read
Baptist Health Cancer Care
While the battle against traditional cigarette smoking has seen remarkable progress, the continued popularity of e-cigarettes, or vaping, continues to be a challenge for public health. The Great American Smokeout, an annual event on the third Thursday of November, encourages people who smoke to quit. And for many, it becomes the first step toward a healthier, smoke-free life.
There is good news. The relentless efforts of public health campaigns have paid off, with adult cigarette smoking in the U.S. dropping to its lowest point in over 60 years. As of late 2023, only 10.8 percent of adults reported smoking cigarettes, a significant decrease from previous years. This decline is a major public health victory, representing millions of people who have lowered their risk for lung cancer, chronic diseases and early death.
Smoking is responsible for more than 80 percent of lung cancer cases, according to the American Cancer Society.
“Each year we see the toll that tobacco and vaping take—not just on individuals, but on families and entire communities,” explains Manmeet Ahluwalia, M.D., chief of medical oncology, chief scientific officer, deputy director and Fernandez Family Foundation Chair in Research at Baptist Health Miami Cancer Institute. “Quitting is a powerful step, and it greatly reduces the risk of cancer, heart disease, and other life-threatening illnesses.”
The number of lung cancer screenings at Miami Cancer Institute has nearly doubled over the past several years as a result of a partnership with LUNGevity, a non-profit organization focused on lung cancer research and patient advocacy. “A pivotal piece of our partnership has been ensuring that we have screening education materials and awareness campaigns in Spanish to meet the needs of the community,” Dr. Ahluwalia notes.
A Shifting Landscape: Fewer Smokers, More Vapers
However, this success is met with a concerning trend: the surge in e-cigarette use. Between 2017 and 2023, while the number of exclusive cigarette smokers fell by 6.8 million, the number of exclusive e-cigarette users grew by 7.2 million. This shows that many people are trading one habit for another, often under the misconception that vaping is a harmless alternative. The percentage of adults using e-cigarettes rose to 6.5 percent in 2023, with the highest rates among young adults aged 18 to 24.
This shift presents a two-front battle. We must continue to support those quitting cigarettes while also addressing the growing addiction to nicotine through vaping.
The Dangers of All Tobacco Products
Whether it's traditional cigarettes or modern e-cigarettes, the health risks are significant and well-documented. Nicotine in any form is highly addictive, and the chemicals involved can cause widespread damage to the body.
Mark Dylewski, M.D., chief of general thoracic surgery at Baptist Health Miami Cancer Institute, puts it bluntly: “Smoking is one of the worst things that you could ever put in your body. It's not just lung cancer that it causes. Smoking is responsible for the majority of healthcare issues. It's actually a top factor that's costing this country a fortune in treating patients for heart disease, peripheral vascular disease, kidney cancer, breast cancer, prostate cancer, lung cancer and gastrointestinal (GI) cancers.”
The consequences of long-term use are severe. “If you want to smoke, you ought to consider that you're likely going to reduce your long-term survival by more than 20 years, if you smoke 20 years or more,” warns Dr. Dylewski.
While often marketed as safer, e-cigarettes are not risk-free. They contain nicotine, which can harm adolescent brain development, and a mix of harmful chemicals like heavy metals and volatile organic compounds.
“Nicotine addiction can start early and is incredibly difficult to overcome, especially with the added appeal of flavored vaping products,” Dr. Ahluwalia notes. “It’s critical that we work together—healthcare providers, families, educators, and policymakers—to help people break free from these products and prevent the next generation from starting.”
Vaping can lead to lung inflammation and other serious respiratory problems. Moreover, recent studies indicate that "dual use"—smoking cigarettes and vaping—can increase the risk of lung cancer by four times, compared to smoking alone.
“Many of my patients are surprised to learn that the harm from vaping can be just as serious as smoking traditional cigarettes,” explains Ian C. Bostock, M.D., thoracic surgeon at Baptist Health Miami Cancer Institute. “Education and early prevention are key to protecting your health and the health of our next generation.”
A Critical Concern: Youth and Flavored Vapes
While youth cigarette smoking has hit an all-time low of just 1.4 percent, the popularity of e-cigarettes among teens remains a serious public health threat. Although the number of middle and high school students who vape dropped in 2024, a large number of them use these products frequently or daily.
A major driver of this trend is the availability of flavored products. In 2024, nearly 88 percent of youth vapers used flavored e-cigarettes, with fruit, candy, and mint flavors being the most popular. The prevalence of disposable vapes makes these products easy to access and conceal, creating a new generation addicted to nicotine.
If you use tobacco or vape, it's also important to discuss lung cancer screening with your doctor. Current guidelines recommend a low-dose CT scan for adults aged 50 to 80 who have a 20-pack-year history of smoking, including those who have quit within the last 15 years.
“As physicians, we see firsthand how difficult it can be to quit smoking, but we also witness incredible transformations when patients commit to quitting,” said Dr. Bostock. “Even small steps toward quitting can lead to big long-term benefits for your health and quality of life.”
Actionable Steps to Quit for Good
Quitting is challenging, but millions of people have done it successfully. Here are some proven strategies to help you on your path:
- Set a Quit Date: Choose a specific day to stop using all nicotine products.
- Create a Quit Plan: Think about your triggers and how you'll manage them. Will you need to avoid certain places or situations? What will you do when a craving hits? Write down your strategies.
- Build a Support System: Tell your friends, family, and coworkers about your plan to quit. Their encouragement can make a huge difference. You can also join a support group or online forum.
- Explore Nicotine Replacement Therapy (NRT): Products like patches, gum, and lozenges can help manage withdrawal symptoms by providing a controlled dose of nicotine without the other harmful chemicals.
- Talk to Your Doctor: A healthcare professional can provide personalized advice and support. They may also recommend prescription medications that have been shown to be effective in helping people quit.
“The Great American Smokeout isn’t just about quitting for one day—it’s about proving to yourself that change is possible,” said Dr. Bostock. “Let this be your starting line toward a healthier future.”
Featured Providers
Manmeet Singh Ahluwalia, MD
Manmeet Ahluwalia, M.D., MBA, FASCO, is the chief scientific officer, chief of medical oncology, deputy director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute.
As a neuro-oncologist, Dr. Ahluwalia’s primary areas of research and patient care are primary brain tumors (tumors originating in the brain that can be cancerous or noncancerous) and brain metastases (cancer that originated elsewhere in the body and has spread to the brain). Dr. Ahluwalia is fluent in English, Hindi and Punjabi.
In 2025, Dr. Manmeet S. Ahluwalia was elected to the American Society for Clinical Investigation (ASCI), one of the oldest and most respected medical honor societies in the United States. This prestigious recognition honors physician-scientists under 50 who have made significant contributions to medical research and clinical care. Dr. Ahluwalia's election marks a historic milestone, as he is the first member from both Baptist Health South Florida and Florida International University Herbert Wertheim College of Medicine to be inducted into the ASCI.
Dr. Ahluwalia completed internal medicine training at Cleveland Clinic Health System and fellowship training at Roswell Park Cancer Institute in 2009. He joined Cleveland Clinic, Ohio and soon became the Miller Family Endowed Chair in Neuro-Oncology and the head of operations at Burkhardt Brain Tumor and Neuro-Oncology Center in 2015. He became a full Professor at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University in 2017. Dr. Ahluwalia obtained an MBA from Case Western - Weatherhead School of Management. Soon after, he moved to Miami Cancer Institute (MCI), intending to build the largest cancer program in South Florida. Alongside his leadership responsibilities, Dr. Ahluwalia holds the Fernandez Family Foundation Endowed Chair in Cancer Research at MCI.
Dr. Ahluwalia is driven by a passion for conquering brain tumors, having seen his grandmother succumb to cancer. For over a decade, he has led practice-changing research for developing new therapies for patients with primary brain tumors and brain metastases, resulting in his 250+ peer- reviewed papers. He designed and led the initial studies on combining immunotherapy/targeted therapy and radiosurgery in brain metastases. He co-led the first-in-man trial of Laser Interstitial Thermal Therapy (LITT) for primary brain tumors, which led to US FDA approval. He also designed and led the LASSR trial exploring LITT for brain metastases and radiation necrosis. He also first authored the landmark paper describing the Phase II trial of SurVaxM for glioblastoma in the Journal of Clinical Oncology.Along with a busy practice, he serves as the Principal Investigator (PI) on a $3.9 million NIH R01-funded grant on quantitative imaging phenotypic classifier development for radiomics in glioblastoma. This is the first NIH R01 grant ever received by Baptist Health. He is also the ‘clinical trial leader’ on the $10.4 million PO1 grant focusing on Glioblastoma gender-specific differences (Cosine Consortium). He is the PI on ongoing paradigm-changing FDA-approval-intent studies on blood- brain barrier disruption by Insightec Neuroblate (LIMITLESS, LIBERATE) through Low-Intensity Focused Ultrasound for primary brain tumors and brain metastases. He also chairs the scientific advisory committee of Guardian Research Network (GRN), a nationwide healthcare alliance.
Dr. Ahluwalia has been a leader in organized efforts in neuro-oncology. He currently serves as the chair of the US National Cancer Institute (NCI) South-West Oncology Group (SWOG) Brain Tumor Working Group and the DEI co-chair of SWOG. He also chairs the Scientific Review Committee of the International Gamma Knife Research Foundation. He also serves as a member of the National Brain Tumor Society (NBTS) Roundtable Committee and as founder PI of the coordinating site for the International Radiosurgery Research Foundation.
Dr. Ahluwalia has received several prestigious awards, including the Fellowship of the American Society of Clinical Oncology (ASCO), the National Cancer Institute/CTEP Career Development Award via the American Brain Tumor Consortium (ABTC), ASCO Leadership Development Program, Most Distinguished Physician Award of AAPI, amongst others.
In his free time, Dr. Ahluwalia enjoys spending time with his children, playing and watching tennis, and watching movies with his family.
Mark Richard Dylewski, MD
Ian Christopher Bostock Rosenzweig, MD
Ian C. Bostock, M.D., MS, FACS, is a board-certified thoracic surgeon at Baptist Health Miami Cancer Institute. He specializes in treating lung and esophageal cancer, mesothelioma, mediastinal and chest wall tumors, and benign esophageal diseases such as reflux, achalasia, and paraesophageal hernias.
Dr. Bostock serves as an associate professor of surgery at Florida International University. Prior to joining Baptist Health, he was an assistant professor in the Department of Cardiothoracic Surgery at the Medical University of South Carolina.
Dr. Bostock earned his medical degree and a master’s degree in Science and Clinical Investigation at Anáhuac University Medical School in Mexico City, Mexico. He completed a general surgery internship at Brigham and Women’s Hospital, Harvard Medical School and a general surgery residency at Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth. He also completed a cardiothoracic surgery fellowship at MD Anderson Cancer Center, The University of Texas.
Dr. Bostock has received several awards for his research in cardiovascular and thoracic surgery. He has published numerous peer-reviewed articles, abstracts and book chapters and has presented at many national academic conferences. He is a fellow of the American College of Surgeons and member of several professional associations.
The focus of Dr. Bostock’s care philosophy is patient-centered care and shared-decision making. He believes that each patient should be viewed as an individual and care plans should reflect the patient’s values, goals and motivations.
Dr. Bostock is fluent in English and Spanish. When he is not treating patients, he enjoys spending time with his wife and kids and dog, Oli. He also likes to stay active, work out on his Peloton bike and travel to exciting places with his wife.
Compassionate, Expert Cancer Care at Baptist Health
Related Stories
View All Articles
How FIU and Baptist Health are Using AI and Sound to Detect Heart Disease Earlier
April 6, 2026
4 min. read